About the Company
matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MTNB News
Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery ...
Latest News for Matinas BioPharma Hldgs Stock (AMEX:MTNB)
12 Health Care Stocks Moving In Tuesday's After-Market Session ...
Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products ...
Matinas BioPharma Holdings Inc
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Matinas BioPharma Holdings Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Matinas BioPharma Holdings Inc (MTNB)
Investing.com - Matinas BioPharma (NYSE: MTNB) reported first quarter EPS of $-0.0259, better than the analyst estimate of $-0.0265. Revenue for the quarter came in at $1.03M ...
MTNB Matinas BioPharma Holdings, Inc.
**NM signifies a non meaningful value. A dash signifies the data is not available.
Matinas BioPharma Holdings Inc.
1 Day MTNB 12.36% DJIA -0.16% Russell 2K 0.61% Health Care/Life Sciences -0.14% ...
Matinas BioPharma Holdings, Inc. (MTNB)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Loading the latest forecasts...